Hjem › Leukemi › Tennessee › Nashville
Kliniske studier for Leukemi i Nashville, TN
12 studier for Leukemi søker deltakere på steder i og rundt Nashville (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
RekruttererFase 3
- Quetzal Site 12, Nashville
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
RekruttererFase 1/2
- Sarah Cannon Research Institute, Nashville
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RekruttererFase 3
- Tennessee Oncology, Nashville
- TriStar Centennial Medical Center, Nashville
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RekruttererFase 1
- Vanderbilt University Medical Center, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekruttererFase 1/2
- TriStar BMT, Nashville
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RekruttererFase 2
- Vanderbilt University, Ingram Cancer Center, Nashville
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RekruttererFase 2/3
- Vanderbilt University Medical Center, Nashville
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RekruttererFase 1
- TriStar Bone Marrow Transplant, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Vanderbilt-Ingram Cancer Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Nashville
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
RekruttererFase 1
- Sarah Cannon Research Institute, Nashville
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
RekruttererFase 1
- TriStar Bone Marrow Transplant, Nashville
Leukemi-studier i andre byer
- Houston, TX28 studier
- Boston, MA25 studier
- New York City, NY19 studier
- Los Angeles, CA16 studier
- Chicago, IL16 studier
- Durham, NC13 studier
- Columbus, OH12 studier
- Baldwin Park, CA12 studier
- Philadelphia, PA12 studier
- Milwaukee, WI11 studier
- Atlanta, GA11 studier
- Seattle, WA11 studier
Andre studier i Nashville
- Ikke-småcellet lungekreft97 studier
- Brystkreft80 studier
- Metastatisk kreft70 studier
- Kolorektal kreft69 studier
- Kreft (alle typer)65 studier
- Eggstokkreft49 studier
- Prostatakreft42 studier
- Lungekreft40 studier
- Plateepitelcancer i hode og hals39 studier
- Pankreaskreft39 studier
- Endometriekreft38 studier
- Melanom33 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.